How profitable is Nkarta Inc. (NKTX)?

In FY 2025 (10-K), NKTX converted $341.6M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / NKTX / financials

EQ (31) HURA (32) NERV (31) OKUR (34) ⌘ Pro Terminal →

Nkarta Inc. (NKTX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: Where is NKTX trading relative to its 50-day, 200-day, and 52-week technical levels?

NKTX last traded at $1.52 (-2.56% on volume of 1,394,464 shares), positioning the stock -36.13% below its 50-day simple moving average ($2.38) and -39.92% below its 200-day simple moving average ($2.53). Across its 52-week range of $1.48 to $3.72, NKTX sits at the 1.8% percentile with a 14-day RSI of 24.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.33 to $1.71).

$1.52 -2.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.51

Nkarta Inc. (NKTX) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $108.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NKTX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NKTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Nkarta Inc. (NASDAQ: NKTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $1.52 (-2.56% 1D, market cap $108.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NKTX ranks #908 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NKTX compare to EQ and HURA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NKTX carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EQ (Equillium Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $108.1M) and HURA (TuHURA Biosciences Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $109.6M). Among the 5-stock peer group, NKTX leads on earnings multiple (N/A) while NKTX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NKTX?

▼

Per NKTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001787400), Nkarta Inc. generated $341.6M in revenue (-4.8% YoY), -$104.1M in net income, and -$89.9M in free cash flow against $404.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.51 (-0.65%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-14.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NKTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (26/100 Composite)

🔍 WHY NKTX SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (27% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 24.3 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.03-13.8% Next Q

Q2 (-2Q)

Grade E$1.75-1.7% Next Q

Q3 (-1Q)

Grade E$1.72-11.6% Next Q

Current

Grade E$1.52-10.5% Hist 90D α

Trajectory: E (34) → E (26)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NKTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NKTX currently carries a cautious 26/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.38) and Max Pain ($1.60) forces dealer call-delta covering toward $3.91.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NKTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NKTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 26%NO 74%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How NKTX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $368.6M

FY24

Rev $358.9M

FY25

Rev $341.6M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$341.6M	52%	-35.7%	-$104.1M	-$89.9M	-35.3%
FY 2024	$358.9M	52%	-35.7%	-$108.8M	-$104.1M	-26.6%
FY 2023	$368.6M	52%	-35.7%	-$117.5M	-$86.2M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NKTX)

✓Walkthrough of NKTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NKTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -50.65%🛡️ HOLDING TREND SUPPORT

2026-11-04O $1.56H $1.56L $1.52C $1.52VOL 1.39M

RES: $2.89SUP: $1.46SMA50: $2.38SMA200: $2.53

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NKTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NKTX Butterfly Map → + Track NKTX →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -4.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NKTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NKTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NKTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NKTX)

Health Care Rank #908 of 1015 ⚔️ EQ vs NKTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NKTX vs. EQ, HURA, NERV, OKUR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Nkarta Inc. (NKTX) ranks #908 by composite RQD confidence (26/100, grade E) and #638 by equity capitalization ($108.9M). Within this direct 5-issuer industry benchmark cohort, NKTX leads on earnings valuation at N/A trailing P/E, while NKTX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OKUR currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with NKTX at 26/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NKTX ACTIVE Nkarta Inc.	E	26/100	—	—	-35.0%	-2.56%	$108.9M	Benchmark Subject
EQ Equillium Inc.	E	31/100	—	—	-35.0%	+0.73%	$108.1M	/eq-vs-nktx →
HURA TuHURA Biosciences Inc.	E	32/100	—	—	-35.0%	-10.88%	$109.6M	/hura-vs-nktx →
NERV Minerva Neurosciences Inc	E	31/100	—	—	-35.0%	+1.08%	$112.0M	/nerv-vs-nktx →
OKUR OnKure Therapeutics Inc. (Class A)	E	34/100	—	—	-35.0%	-1.14%	$104.9M	/okur-vs-nktx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001787400 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nkarta Inc. (NKTX) reported GAAP revenue of $341.6M (-4.8% vs. FY2024 revenue of $358.9M , and -7.3% cumulative change since FY2023) , GAAP net income of -$104.1M, operating cash flow of -$88.7M, and free cash flow of -$89.9M (+13.6% YoY). On the balance sheet, NKTX closed FY2025 with $404.2M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$341.6M	-$104.1M	-$88.7M	-$89.9M	$404.2M	—
FY2024 (FY)	2024-12-31	$358.9M	-$108.8M	-$99.7M	-$104.1M	$501.2M	—
FY2023 (FY)	2023-12-31	$368.6M	-$117.5M	-$86.2M	-$86.2M	—	—

3. NKTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NKTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NKTX compare to EQ and HURA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NKTX?

Where is NKTX trading relative to its 50-day, 200-day, and 52-week technical levels?

NKTX last traded at $1.52 (-2.56% on volume of 1,394,464 shares), positioning the stock -36.13% below its 50-day simple moving average ($2.38) and -39.92% below its 200-day simple moving average ($2.53). Across its 52-week range of $1.48 to $3.72, NKTX sits at the 1.8% percentile with a 14-day RSI of 24.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.33 to $1.71).

Direct Sub-Reports: NKTX RQD Cockpit NKTX 12M Forecast NKTX Earnings & Move NKTX Dividends & DRIP NKTX Insiders & 13F NKTX Whale Options NKTX Profit Sankey NKTX News & Why

ROARABLE RATING BRIEF • RQD 26/100 (E) ✓ SEC XBRL & RQD VERIFIED

NKTX — Nkarta Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Nkarta Inc. (NKTX) earns a live Roarable RQD composite score of 26/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.52 (-2.56% 1D, market capitalization $108.9M).

Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (7/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Nkarta Inc. (NKTX) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry..1B. — describes its specific products, customers, or revenue model beyond the sector and industry classification. The reported revenue for the periods provided is —.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Nkarta Inc. (NKTX) reported $341.6M in annual revenue (up from $358.9M in FY2024, -4.8% YoY) and -$104.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($368.6M revenue, -$117.5M net income) through FY2025, NKTX scaled operating cash flow to -$88.7M and free cash flow to -$89.9M, backed by $404.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 26/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.48 – $3.72 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), NKTX carries a macro regime beta of 1.00 and gross margin of —.

Key Question #1: Can NKTX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $341.6M and free cash flow of -$89.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is NKTX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NKTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nkarta Inc. (NKTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NKTX Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 1d ago

Nkarta, Inc. Estimates – NASDAQ:NKTX

TradingView report covering Nkarta Inc. (NKTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Nkarta, Inc. (NKTX) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Nkarta Inc. (NKTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com India • 2d ago

H.C. Wainwright initiates Nkarta stock coverage with buy rating By Investing.com

Investing.com India report covering Nkarta Inc. (NKTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 2d ago

Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?

Simply Wall St report covering Nkarta Inc. (NKTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 2d ago

Nkarta (NKTX) Edges Higher to $2.58 as Traders Watch $2.45 Support and $2.71 Resistance - ATR Trailing Stop

https://www.siam.in/ report covering Nkarta Inc. (NKTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 2d ago

Nkarta (NKTX) Slips 1.96% to $2.21 as Shares Sit Near Lower End of Trading Range - Retracement Entry

https://www.siam.in/ report covering Nkarta Inc. (NKTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 2d ago

HC Wainwright & Co. Assumes Nkarta at Buy, Announces Price Target of $12

HC Wainwright & Co. analyst Douglas Tsao assumes Nkarta (NASDAQ:NKTX) with a Buy rating and announces Price Target of $12.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NKTX Bull vs. Bear Conversation Board — What's Your Call at $1.52?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NKTX 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $1.84 (+17.9%)

📌 Pinned Debate

A recent H.C. Wainwright initiation with a buy rating is cited in the news wire, though the source provides no price target or supporti

Here is why I am bullish on NKTX here at $1.56: A recent H.C. Wainwright initiation with a buy rating is cited in the news wire, though the source provides no price target or supporting detail.. Compare NKTX's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $1.48 are getting bought.

VolSurface_Trader 🐂 BULL

Both sides have a point here — NKTX's 7/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $1.26 (-19.2%)

Spot @ $1.56

The RQD rating of 31 (grade E) reflects zero revenue, -35% ROIC, zero free cash flow yield, and an Altman Z-Score of 0.2.

Careful chasing NKTX at $1.56. The RQD rating of 31 (grade E) reflects zero revenue, -35% ROIC, zero free cash flow yield, and an Altman Z-Score of 0.2.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.26 on multiple compression.